Unicycive Therapeutics (UNCY)
Develops kidney-disease candidates for dialysis and acute injury.
Something off on this page? Send us feedback.
Develops two in-licensed renal-disease candidates: OLC, an oral phosphate binder for hyperphosphatemia in dialysis patients, and UNI-494 for acute-kidney-injury-related conditions. The pre-commercial business depends on advancing these programs, FDA action, and third-party manufacturing readiness.
Develops two in-licensed candidates for kidney disease: oxylanthanum carbonate (OLC) for hyperphosphatemia in dialysis patients and UNI-494 for conditions related to acute kidney injury.
OLC is an investigational oral phosphate binder. Its resubmitted new drug application received a second Complete Response Letter tied to third-party manufacturing deficiencies; FDA did not cite clinical efficacy or safety concerns or request additional data.
UNI-494 has orphan-drug designation for preventing delayed graft function in kidney-transplant patients and has completed an early safety study. As a pre-commercial business, development work, FDA action, and third-party manufacturing readiness shape its operating path.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 27, 2026 | H.C. Wainwright | Target | Target: — | Target: $22 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $61.4M · Total debt $671.0K · Total assets $72.0M · Shareholders' equity $53.3M
- Revenue
- $0
- Operating income
- −$10.1M
- Net income
- −$1.7M
No dividends on record.
| Institutions | 41.88% | 11.67M shares | |
|---|---|---|---|
| 90 holders · as of Jun 30, 2026 | |||
| Insiders | 6.43% | 1.79M shares | |
| 1 holder · as of Aug 26, 2025 | |||
| Strategic holders | 4.21% | 1.17M shares | |
| 1 holder · as of Jan 23, 2026 | |||
| Other | 47.48% | 13.23M shares | |
| remainder | |||
27.86M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
RA Capital Management, L.P.Institution | 10.06% | 2.80M | filed May 15, 2026 |
Gaurav AggarwalInsiderdirector | 6.43% | 1.79M | filed Aug 26, 2025 |
BlackRock, Inc.Institution | 5.07% | 1.41M | as of Jun 30, 2026 |
Nantahala Capital Management, LLCInstitution | 5.03% | 1.40M | as of Jun 30, 2026 |
Integrated Core Strategies (US) LLCStrategic | 4.21% | 1.17M | filed Jan 23, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Ardelyx
XPHOZAH is an approved phosphate absorption inhibitor for dialysis
- Fresenius Medical Care (ADR)
Velphoro is an iron-based phosphate binder for dialysis
- Akebia Therapeutics
Auryxia controls serum phosphorus in adults on dialysis
- Sanofi (ADR)
Renvela and Renagel are established dialysis phosphate binders
- Takeda (ADR)
Fosrenol is a lanthanum carbonate phosphate binder
- OPKO Health
Alpharen is a development-stage potential phosphate-binder entrant
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Unicycive Therapeutics | $4.99 | +0.60% | $127.4M | — | — | — | — |
| Ardelyx | $3.59 | −1.21% | $864.6M | — | — | 1.9 | +23.8% |
| Fresenius Medical Care (ADR) | $22.50 | −0.04% | $11.94B | 11.6 | 8.7 | 0.5 | −0.7% |
| Akebia Therapeutics | $0.9750 | +0.13% | $251.8M | — | — | 1.1 | −21.4% |
| Sanofi (ADR) | $42.52 | +0.12% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Takeda (ADR) | $18.89 | −0.34% | $60.11B | 52.5 | 59.9 | 2.0 | +4.2% |
| OPKO Health | $1.73 | 0.00% | $1.26B | — | — | 2.1 | +4.3% |
| Median | 52.5 | 34.3 | 1.9 | +4.2% |